On November 11, 2025, the 76th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) concluded in Washington, D.C., USA! As the premier annual event in the field of hepatology, this year’s meeting brought together leading liver disease experts and scholars from around the world to share the latest academic achievements in liver disease development, serving as an important platform for understanding the future of hepatology. At the conference, Eieling Technology presented its innovative product portfolio— Liverscan® and FattaLab®—to the attending experts and scholars, comprehensively demonstrating the company’s innovative strength and highlights in the field of liver health.
This marks Eieling’s second appearance at the American Liver Conference since 2024. This year, both Liverscan® and FattaLab® were showcased, featuring unique and innovative technologies, a portable design, and superior performance, precisely meeting current liver testing needs and attracting widespread attention from experts both domestically and internationally. During the exhibition, the team engaged in in-depth exchanges and discussions with visiting clients, experts, and scholars regarding the future trends of non-invasive liver solutions.
At this exhibition, the Liverscan® became the focus of attention. This device provides quantitative parameters for liver fibrosis and steatosis, and displays real-time ultrasound images of the acquisition location, significantly reducing operational complexity. During the examination, Liverscan® can accurately identify liver regions in individuals with high BMI, enabling efficient liver examination without switching probes, precisely meeting the clinical needs of frequent follow-up liver examinations. This facilitates early detection and timely intervention of liver diseases, providing strong support for the entire process of early liver screening and treatment. Liverscan® has demonstrated excellent detection efficiency and broad clinical application value in various scenarios, including primary healthcare institutions, hospitals, and clinics.
In addition to Liverscan®, the FattaLab®made its debut at the American Liver Conference. This device directly addresses the current pain points and challenges in fatty liver detection, attracting widespread attention for its groundbreaking design and functionality. The Eieling team explained that FattaLab® can complete fatty liver detection and output quantitative data in just 10 seconds, and its ultra-lightweight 120g body attracted many attendees and potential customers to try it out. While achieving a lightweight design, its patented Auto Intra-Focus Fusion human liver fat detection algorithm ensures high accuracy and reliability. Based on its unique product advantages, FattaLab® has won the 2026 CES® Innovation Award (organized by the Consumer Technology Association (CTA), considered the “Oscars” of the global consumer technology industry). This award is a high recognition of its innovative design and technological strength, affirming its revolutionary solution in the field of fatty liver screening.
The continued growth of the global liver disease population places higher demands on the convenience, intelligence, speed, and accuracy of liver examinations. Eieling Technology’s liver health solutions are gradually covering diverse scenarios from medical institutions to homes, realizing the vision of “health for everyone.”
The product’s debut at the American Liver Health Conference not only allowed attendees to directly experience its technological advantages but also marked a significant step in Eieling Technology’s globalization strategy. Moving forward, Eieling Technology will continue to inject innovative vitality into the liver health field, leading the cutting-edge development of non-invasive liver testing technologies.